Thomas W. Gero

Affiliations: 
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States 
Area:
BCL2, Kras, eya1
Google:
"Thomas Gero"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Hwang GH, Pazyra-Murphy MF, Seo HS, et al. (2024) A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma. Cancer Research. 84: 872-886
To C, Beyett TS, Jang J, et al. (2022) An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nature Cancer
Gero TW, Heppner DE, Beyett TS, et al. (2022) Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Bioorganic & Medicinal Chemistry Letters. 128718
Li Z, Powell CE, Groendyke BJ, et al. (2020) Discovery of a Series of Benzopyrimidodiazepinone TNK2 Inhibitors via Scaffold Morphing. Bioorganic & Medicinal Chemistry Letters. 127456
Groendyke BJ, Powell CE, Feru F, et al. (2020) Benzopyrimidodiazepinone inhibitors of TNK2. Bioorganic & Medicinal Chemistry Letters. 126948
Zeng M, Xiong Y, Safaee N, et al. (2019) Exploring Targeted Degradation Strategy for Oncogenic KRAS. Cell Chemical Biology
De Clercq DJH, Heppner DE, To C, et al. (2019) Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. Acs Medicinal Chemistry Letters. 10: 1549-1553
To C, Jang J, Chen T, et al. (2019) Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discovery
Grimster NP, Anderson E, Alimzhanov M, et al. (2018) Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors. Journal of Medicinal Chemistry
Zeng M, Lu J, Li L, et al. (2017) Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chemical Biology
See more...